Table 1.
Correlation of GLUT1 mRNA expression with clinicopathological features in the TCGA cohort.
| Characteristic | levels | GLUT1 expression | P | |
|---|---|---|---|---|
| Low (%) | High (%) | |||
| Age | <=60 | 36 (22.2%) | 47 (29%) | 0.116 |
| >60 | 45 (27.8%) | 34 (21%) | ||
| Gender | Female | 11 (6.8%) | 12 (7.4%) | 1.000 |
| Male | 70 (43.2%) | 69 (42.6%) | ||
| T stage | T1 | 16 (11%) | 11 (7.6%) | 0.085 |
| T2 | 12 (8.3%) | 25 (17.2%) | ||
| T3 | 39 (26.9%) | 38 (26.2%) | ||
| T4 | 3 (2.1%) | 1 (0.7%) | ||
| N stage | N0 | 27 (18.8%) | 39 (27.1%) | 0.291 |
| N1 | 35 (24.3%) | 28 (19.4%) | ||
| N2 | 4 (2.8%) | 5 (3.5%) | ||
| N3 | 4 (2.8%) | 2 (1.4%) | ||
| M stage | M0 | 58 (45%) | 63 (48.8%) | 0.486 |
| M1 | 5 (3.9%) | 3 (2.3%) | ||
| Pathologic stage | Stage I | 8 (5.6%) | 8 (5.6%) | 0.064 |
| Stage II | 26 (18.3%) | 43 (30.3%) | ||
| Stage III | 30 (21.1%) | 19 (13.4%) | ||
| Stage IV | 5 (3.5%) | 3 (2.1%) | ||
| Histological type | Adenocarcinoma | 61 (37.7%) | 19 (11.7%) | <0.001 |
| Squamous Cell Carcinoma | 20 (12.3%) | 62 (38.3%) | ||
| Histologic grade | G1 | 2 (1.6%) | 14 (11.1%) | 0.006 |
| G2 | 33 (26.2%) | 33 (26.2%) | ||
| G3 | 26 (20.6%) | 18 (14.3%) | ||
Bold values indicate P < 0.05.